Janney Montgomery Scott
JANX icon

Janney Montgomery Scott’s Janux Therapeutics JANX Stock Holding History

Janney Montgomery Scott’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-51,548
Closed -$553K – 2777
2023
Q4 		$553K Buy
+51,548
New +$446K ﹤0.01% 1822
2021
Q4 		– Sell
-40,860
Closed -$884K – 2395
2021
Q3 		$884K Buy
+40,860
New +$1.18M ﹤0.01% 1346

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janney Montgomery Scott's JANX Position: Q1 2024 in Review

Janney Montgomery Scott sold out of Janux Therapeutics (JANX) in Q1 2024, closing a stake of 51,548 shares — an estimated $553K sold.

Janney Montgomery Scott first reported a position in JANX in Q3 2021 and held it in 2 quarters. The position peaked at $884K in Q3 2021. 121 funds tracked by Wall St. Rank hold JANX as of Q1 2024.

  • Janney Montgomery Scott reported no remaining Janux Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Janney Montgomery Scott sold 51,548 Janux Therapeutics shares in Q1 2024, an estimated $553K.
  • Janney Montgomery Scott first reported a position in Janux Therapeutics in Q3 2021 and held it in 2 quarters.
  • Janney Montgomery Scott's Janux Therapeutics position peaked at $884K in Q3 2021.
  • 121 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2024.

Based on Janney Montgomery Scott's 13F filing for Q1 2024, filed 1 May 2024.